Document is current
Any future updates will be listed below
-
Authors
Chastek, Benjamin
Carrera, Adam
Landis, Christina https://orcid.org/0000-0002-1246-1635
Snyder, Daniel
Abedinzadeh, Laleh https://orcid.org/0009-0004-7568-2787
Bancroft, Tim https://orcid.org/0000-0002-4998-582X
Nesheim, Jeffrey
Kennelly, Michael https://orcid.org/0000-0002-7044-506X
Staskin, David
-
Funding
Funding for this research was provided by:
Sumitomo Pharma America
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 15 February 2024
First Online: 23 March 2024
Declarations
:
: B Chastek, C Landis, and T Bancroft are employees of Optum. A Carrera, D Snyder, L Abedinzadeh, and J Nesheim are employees of Sumitomo Pharma America (formerly Urovant Sciences). M Kennelly is a consultant for AbbVie, Axonics, BD, Boston Scientific, Coloplast, Medtronic, and Sumitomo Pharma America and has received grant or research study funding from AbbVie, Axonics, Boston Scientific, Coloplast, Cook Myosite, EBT Medical, FemPulse, Medtronic, and SpineX. D Staskin is a consultant for Astellas, UroCure, and Sumitomo Pharma America; is an investigator and meeting participant/lecturer for Astellas and Sumitomo Pharma America; and holds other interests in UroCure.
: This retrospective database analysis used deidentified claims data from the Optum Research Database (with permission from Optum), which is compliant with the Health Insurance Portability and Accountability Act to protect patient privacy.
